New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its ...
In a gold-standard model of obesity, treatment with ARD-201 resulted in approximately 19% body weight reduction after 30 days of treatment. ARD-201 was also associated with attenuated weight regain ...
Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients ...
Aardvark Therapeutics, Inc. (NASDAQ:AARD) has filed to raise $100 million in an IPO of its common stock, according to SEC S-1 registration information. The firm is a clinical-stage biopharma ...
Live webcasts of each presentation will be accessible on the company’s website, www.aardvarktherapeutics.com, under the investors section and an archived recording will be available on the website for ...
(MENAFN- GlobeNewsWire - Nasdaq) Aardvark to host Investor Webinar with members of the management team, leading key opinion leaders and patient advocates on November 5, 2025 SAN DIEGO, Oct. 22, 2025 ...
Tactical products and equipment specialist AARDVARK Tactical is launching a new and improved version of their website in April of 2022. This site will be geared towards more efficient product browsing ...
Live webcasts of each presentation will be accessible on the company’s website, www.aardvarktherapeutics.com, under the investors section and an archived recording will be available on the website for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback